Nanovehicular Intracellular Delivery Systems

Kostarelos, 2003, Rational design and engineering of delivery systems for therapeutics: Biomedical exercises in colloid and surface science, Adv Colloid Interface Sci, 106, 147, 10.1016/S0001-8686(03)00109-X Moses, 2003, Advancing the field of drug delivery: Taking aim at cancer, Cancer Cell, 4, 337, 10.1016/S1535-6108(03)00276-9 Shargel, 1999 van de Waterbeemd, 2003, ADMET in silico modelling: Towards prediction paradise?, Nat Rev Drug Discov, 2, 192, 10.1038/nrd1032 Okada, 1995, Biodegradable microspheres in drug delivery, Crit Rev Ther Drug Carrier Syst, 12, 1, 10.1615/CritRevTherDrugCarrierSyst.v12.i1.10 Varde, 2004, Microspheres for controlled release drug delivery, Expert Opin Biol Ther, 4, 35, 10.1517/14712598.4.1.35 Kohane, 2006, Microparticles and nanoparticles for drug delivery, Biotechnol Bioeng, 96, 203, 10.1002/bit.21301 Kasturi, 2005, Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines, Biomaterials, 26, 6375, 10.1016/j.biomaterials.2005.03.043 Vicent, 2006, Polymer conjugates: Nanosized medicines for treating cancer, Trends Biotechnol, 24, 39, 10.1016/j.tibtech.2005.11.006 Lee, 2005, Designing dendrimers for biological applications, Nat Biotechnol, 23, 1517, 10.1038/nbt1171 Sato, 1992, Recent aspects in the use of liposomes in biotechnology and medicine, Prog Lipid Res, 31, 345, 10.1016/0163-7827(92)90001-Y Bendas, 2001, Immunoliposomes: A promising approach to targeting cancer therapy, BioDrugs, 15, 215, 10.2165/00063030-200115040-00002 Paciotti, 2004, Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery, Drug Deliv, 11, 169, 10.1080/10717540490433895 Akerman, 2002, Nanocrystal targeting in vivo, Proc Natl Acad Sci USA, 99, 12617, 10.1073/pnas.152463399 Chen, 2004, Preparation and characterization of porous hollow silica nanoparticles for drug delivery application, Biomaterials, 25, 723, 10.1016/S0142-9612(03)00566-0 Ito, 2005, Medical application of functionalized magnetic nanoparticles, J Biosci Bioeng, 100, 1, 10.1263/jbb.100.1 Arias, 2007, Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications, Int J Pharmaceut, 339, 237, 10.1016/j.ijpharm.2007.02.028 Ferrari, 2005, Cancer nanotechnology: Opportunities and challenges, Nat Rev Cancer, 5, 161, 10.1038/nrc1566 Petrak, 2005, Essential properties of drug-targeting delivery systems, Drug Discov Today, 10, 1667, 10.1016/S1359-6446(05)03698-6 Opanasopit, 2002, Factors affecting drug and gene delivery: Effects of interaction with blood components, Crit Rev Ther Drug Carrier Syst, 19, 191, 10.1615/CritRevTherDrugCarrierSyst.v19.i3.10 Gabriele, 1993, Liver contrast media for magnetic resonance imaging: Interactions between pharmacokinetics and imaging, Invest Radiol, 28, 753, 10.1097/00004424-199308000-00018 Moghimi, 2001, Long-circulating and target-specific nanoparticles: Theory to practice, Pharmacol Rev, 53, 283 Boddy, 1989, Efficiency of drug targeting: Steady-state considerations using a three-compartment model, Pharm Res, 6, 367, 10.1023/A:1015971113161 Morgan, 1990, Interactions of a model block copolymer drug delivery system with two serum proteins and myoglobin, Biochem Soc Trans, 18, 1021, 10.1042/bst0181021 O'Mullane, 1988, Adsorption of fibrinogen on to polystyrene latex coated with the non-ionic surfactant, poloxamer 338, Biomaterials, 9, 203, 10.1016/0142-9612(88)90124-X Ayhan, 1995, Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties, J Biomater Sci Polym Ed, 7, 329, 10.1163/156856295X00355 Saltzman, 2001 Mager, 2006, Target-mediated drug disposition and dynamics, Biochem Pharmacol, 72, 1, 10.1016/j.bcp.2005.12.041 Saga, 1995, Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier, Proc Natl Acad Sci USA, 92, 8999, 10.1073/pnas.92.19.8999 Kostarelos, 2004, Binding and interstitial penetration of liposomes within avascular tumor spheroids, Int J Cancer, 112, 713, 10.1002/ijc.20457 Hawley, 1995, Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics, Advan Drug Del Rev, 17, 129, 10.1016/0169-409X(95)00045-9 Moghimi, 1996, Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues, Prog Biophys Mol Biol, 65, 221, 10.1016/S0079-6107(96)00012-0 Mager, 2005, Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys, Pharm Res, 22, 58, 10.1007/s11095-004-9009-z Galindo-Rodriguez, 2005, Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies, Crit Rev Ther Drug Carrier Syst, 22, 419, 10.1615/CritRevTherDrugCarrierSyst.v22.i5.10 Papisov, 1996, Drug delivery to lymphatic tissue, Crit Rev Ther Drug Carrier Syst, 13, 57 Ferl, 2006, A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments, Mol Cancer Ther, 5, 1550, 10.1158/1535-7163.MCT-06-0072 Flessner, 1991, Peritoneal transport physiology: Insights from basic research, J Am Soc Nephrol, 2, 122, 10.1681/ASN.V22122 McLennan, 2005, Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep, J Pharmacol Exp Ther, 313, 345, 10.1124/jpet.104.078790 Park, 2002, Tumor-directed targeting of liposomes, Biosci Rep, 22, 267, 10.1023/A:1020190606757 Gabizon, 2004, Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates, Adv Drug Deliv Rev, 56, 1177, 10.1016/j.addr.2004.01.011 van Vlerken, 2006, Multi-functional polymeric nanoparticles for tumour-targeted drug delivery, Expert Opin Drug Deliv, 3, 205, 10.1517/17425247.3.2.205 King, 1998, The biochemical and physiological characteristics of receptors, Adv Drug Deliv Rev, 29, 197, 10.1016/S0169-409X(97)00079-3 Erdogan, 2006, Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes, Mol Pharm, 3, 525, 10.1021/mp060055t Gabizon, 2006, Pros and cons of the liposome platform in cancer drug targeting, J Liposome Res, 16, 175, 10.1080/08982100600848769 Copeland, 2006, Drug-target residence time and its implications for lead optimization, Nat Rev Drug Discov, 5, 730, 10.1038/nrd2082 Colburn, 2003, Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling, Clin Pharmacokinet, 42, 997, 10.2165/00003088-200342120-00001 Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat Rev Cancer, 2, 750, 10.1038/nrc903 Kukowska-Latallo, 2005, Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer, Cancer Res, 65, 5317, 10.1158/0008-5472.CAN-04-3921 Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res, 66, 6732, 10.1158/0008-5472.CAN-05-4199 Maeda, 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting, Adv Enzyme Regul, 41, 189, 10.1016/S0065-2571(00)00013-3 Lopes de Menezes, 1998, In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma, Cancer Res, 58, 3320 Tardi, 2002, The development of liposomes for enhanced delivery of chemotherapeutics to tumors, 119 Klapper, 1997, A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors, Oncogene, 14, 2099, 10.1038/sj.onc.1201029 Hurwitz, 1995, Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake, Proc Natl Acad Sci USA, 92, 3353, 10.1073/pnas.92.8.3353 Nielsen, 2006, A novel assay for monitoring internalization of nanocarrier coupled antibodies, BMC Immunol, 7, 24, 10.1186/1471-2172-7-24 Goren, 1996, Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies, Br J Cancer, 74, 1749, 10.1038/bjc.1996.625 Hosokawa, 2003, Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner, Br J Cancer, 89, 1545, 10.1038/sj.bjc.6601341 Sapra, 2004, Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes, Clin Cancer Res, 10, 2530, 10.1158/1078-0432.CCR-03-0376 Sapra, 2002, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs, Cancer Res, 62, 7190 Kurihara, 1999, Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier, Cancer Res, 59, 6159 Brandli, 1991, Transcytosis of epidermal growth factor. The epidermal growth factor receptor mediates uptake but not transcytosis, J Biol Chem, 266, 8560, 10.1016/S0021-9258(18)93011-5 Shah, 1996, Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells, J Pharm Sci, 85, 1306, 10.1021/js9601400 Olivier, 2005, Drug transport to brain with targeted nanoparticles, NeuroRx, 2, 108, 10.1602/neurorx.2.1.108 Bollinger, 2005, Ceramide-enriched membrane domains, Biochim Biophys Acta, 1746, 284, 10.1016/j.bbamcr.2005.09.001 Handl, 2004, Hitting multiple targets with multimeric ligands, Expert Opin Ther Targets, 8, 565, 10.1517/14728222.8.6.565 de la Fuente, 2004, Understanding carbohydrate-carbohydrate interactions by means of glyconanotechnology, Glycoconj J, 21, 149, 10.1023/B:GLYC.0000044846.80014.cb Shaunak, 2004, Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation, Nat Biotechnol, 2, 977, 10.1038/nbt995 Plank, 1994, The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems, J Biol Chem, 269, 12918, 10.1016/S0021-9258(18)99963-1 Dokka, 2000, 2000 Novel non-endocytic delivery of antisense oligonucleotides, Adv Drug Deliv Rev, 44, 35, 10.1016/S0169-409X(00)00082-X Zauner, 2001, In vitro uptake of polystyrene microspheres: Effect of particle size, cell line, and cell density, J Control Release, 71, 39, 10.1016/S0168-3659(00)00358-8 Rejman, 2004, Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis, Biochem J, 377, 159, 10.1042/bj20031253 Win, 2005, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, 2713, 10.1016/j.biomaterials.2004.07.050 Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: Effect of particle size, Pharm Res, 13, 1838, 10.1023/A:1016085108889 Hartig, 2006, Improved polyelectrolyte complex physicochemistry by non-stoichiometric mixing of polyions with similar molecular weights, Biomacromol, 8, 265, 10.1021/bm0604754 Hartig, 2007, Kinetic analysis of nanoparticulate polyelectrolyte complex interactions with endothelial cells by flow cytometry, Biomaterials, 28, 3843, 10.1016/j.biomaterials.2007.04.027 Carlesso, 2007, Enhancement of binding and gene delivery to endothelial cells by targeted nanoparticulate polyelectrolyte complexes, Mol Ther Foged, 2005, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model, Int J Pharm, 298, 315, 10.1016/j.ijpharm.2005.03.035 Almofti, 2003, Lipoplex size determines lipofection efficiency with or without serum, Mol Membr Biol, 20, 35, 10.1080/09687680210035104 Winter, 2003, Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging, Cancer Res, 63, 5838 Senior, 1985, Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection, Biochim Biophys Acta, 839, 1, 10.1016/0304-4165(85)90174-6 Dams, 2000, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes, J Pharmacol Exp Ther, 292, 1071 Drummond, 1999, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol Rev, 51, 691 Moghimi, 1999, Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography, Adv Drug Deliv Rev, 37, 295, 10.1016/S0169-409X(98)00099-4 Moghimi, 1995, Exploiting bone marrow microvascular structure for drug delivery and future therapies, Advan Drug Del Rev, 17, 61, 10.1016/0169-409X(95)00041-5 Moghimi, 2005, Nanomedicine: Current status and future prospects, FASEB J, 19, 311, 10.1096/fj.04-2747rev Awasthi, 2003, Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits, Int J Pharm, 253, 121, 10.1016/S0378-5173(02)00703-2 Panyam, 2003, Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells, Pharm Res, 20, 212, 10.1023/A:1022219003551 Hartig, 2007, Multifunctional nanoparticulate polyelectrolyte complexes, Pharm Res, 24, 2353, 10.1007/s11095-007-9459-1 Panyam, 2004, Targeting intracellular targets, Curr Drug Deliv, 1, 235, 10.2174/1567201043334768 Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int J Pharm, 307, 93, 10.1016/j.ijpharm.2005.10.010 Panyam, 2003, Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles, Int J Pharm, 262, 1, 10.1016/S0378-5173(03)00295-3 Conner, 2002, Regulated portals of entry into the cell, Nature, 422, 37, 10.1038/nature01451 Maxfield, 2004, Endocytic recycling, Nat Rev Mol Cell Biol, 5, 121, 10.1038/nrm1315 Goldstein, 1985, Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system, Annu Rev Cell Biol, 1, 1, 10.1146/annurev.cb.01.110185.000245 Sangiorgio, 2004, GPI-anchored proteins and lipid rafts, Ital J Biochem, 53, 98 Ferrari, 2003, Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time, Mol Ther, 8, 284, 10.1016/S1525-0016(03)00122-9 Cohen, 2004, Role of caveolae and caveolins in health and disease, Physiol Rev, 84, 1341, 10.1152/physrev.00046.2003 Urban, 2000, Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells, J Biol Chem, 275, 33409, 10.1074/jbc.M004031200 Fabriek, 2005, The macrophage scavenger receptor CD163, Immunobiology, 210, 153, 10.1016/j.imbio.2005.05.010 Han, 2006, In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes, Int J Pharm, 313, 181, 10.1016/j.ijpharm.2006.02.007 Adrian, 2006, Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems, J Hepatol, 44, 560, 10.1016/j.jhep.2005.08.027 Yan, 2005, The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse, Biochem Biophys Res Commun, 328, 57, 10.1016/j.bbrc.2004.12.137 Kunisawa, 2005, Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release, J Control Release, 105, 344, 10.1016/j.jconrel.2005.03.020 Holthuis, 2005, Lipid traffic: Floppy drives and a superhighway, Nat Rev Mol Cell Biol, 6, 209, 10.1038/nrm1591 Khalil, 2006, Uptake pathways and subsequent intracellular trafficking in oncoviral gene delivery, Pharmacol Rev, 58, 32, 10.1124/pr.58.1.8 Kirkham, 2005, Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers, Biochim Biophys Acta, 1746, 349, 10.1016/j.bbamcr.2005.11.005 Muro, 2003, Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress, Am J Physiol Cell, 285, C1339, 10.1152/ajpcell.00099.2003 Muro, 2004, Endothelial endocytic pathways: Gates for vascular drug delivery, Curr Vasc Pharmacol, 2, 281, 10.2174/1570161043385736 Ding, 2006, Advanced drug delivery systems that target the vascular endothelium, Mol Interv, 6, 98, 10.1124/mi.6.2.7 Sahoo, 2005, Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention, Mol Pharm, 2, 373, 10.1021/mp050032z Salaun, 2004, Lipid rafts and the regulation of exocytosis, Traffic, 5, 255, 10.1111/j.1600-0854.2004.0162.x Ambudkar, 2006, The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1), Europ J Pharmaceut Sci, 27, 392, 10.1016/j.ejps.2005.10.010 Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev Pharmacol Toxicol, 39, 361, 10.1146/annurev.pharmtox.39.1.361 Shitara, 2006, Transporters as a determinant of drug clearance and tissue distribution, Europ J Pharmaceut Sci, 27, 425, 10.1016/j.ejps.2005.12.003 Florence, 2001, Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas, Adv Drug Deliv Rev, 50, S69, 10.1016/S0169-409X(01)00184-3 Watson, 2005, Intracellular trafficking pathways and drug delivery: Fluorescence imaging of living and fixed cells, Adv Drug Deliv Rev, 57, 43, 10.1016/j.addr.2004.05.003 Zeng, 2003, Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1, J Biol Chem, 278, 45931, 10.1074/jbc.M307722200 Levchenko, 2003, Tat peptide-mediated intracellular delivery of liposomes, Method Enzymol, 372, 339, 10.1016/S0076-6879(03)72019-9 Sharma, 2002, Endocytosis of lipid rafts: An identity crisis, Semin Cell Dev Biol, 13, 205, 10.1016/S1084-9521(02)00049-6 Richard, 2003, Cell-penetrating peptides: A reevaluation of the mechanism of cellular uptake, J Biol Chem, 278, 585, 10.1074/jbc.M209548200 Johannes, 2002, Clathrin-dependent or not: Is it still the question?, Traffic, 3, 443, 10.1034/j.1600-0854.2002.30701.x Mousavi, 2004, Clathrin-dependent endocytosis, Biochem J, 377, 1, 10.1042/bj20031000 Amyere, 2002, Origin, originality, functions, subversions and molecular signalling of macropinocytosis, Int J Med Microbiol, 291, 487, 10.1078/1438-4221-00157 Catizone, 1993, A quantitative assessment of non specific pinocytosis by human endothelial cells surviving in vitro, Cell Mol Biol (Noisy-le-grand), 39, 155 Behrens, 2002, Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport, Pharm Res, 19, 1185, 10.1023/A:1019854327540 Zhao, 2006, Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF), J Biol Chem, 281, 15757, 10.1074/jbc.M510714200 Brown, 1976, Receptor-mediated control of cholesterol metabolism, Science, 191, 150, 10.1126/science.174194 Dobrian, 1996, Increased macrophage uptake of irreversibly glycated albumin modified-low density lipoproteins of normal and diabetic subjects is mediated by non-saturable mechanisms, Biochim Biophys Acta, 1317, 5, 10.1016/0925-4439(96)00017-8 Panagi, 2001, Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles, Int J Pharm, 221, 143, 10.1016/S0378-5173(01)00676-7 Berk, 1999, Mechanisms of cellular uptake of long chain free fatty acids, Mol Cell Biochem, 192, 17, 10.1023/A:1006832001033 Szleifer, 1997, Protein adsorption on surfaces with grafted polymers: A theoretical approach, Biophys J, 72, 595, 10.1016/S0006-3495(97)78698-3 Moghimi, 2002, Liposome recognition by resident and newly recruited murine liver macrophages, J Liposome Res, 12, 67, 10.1081/LPR-120004778 Kunath, 2003, Integrin targeting using RGD-PEI conjugates for in vitro gene transfer, J Gene Med, 5, 588, 10.1002/jgm.382 Dauty, 2002, Intracellular delivery of nanometric DNA particles via the folate receptor, Bioconjugate Chem, 13, 831, 10.1021/bc0255182 Lin, 2004, The effect of polymer chain length and surface density on the adhesiveness of functionalized polymersomes, Langmuir, 20, 5493, 10.1021/la036417a Torchilin, 2001, TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors, Proc Natl Acad Sci USA, 98, 8786, 10.1073/pnas.151247498 Chen, 2005, Architectural and structural optimization of the protective polymer layer for enhanced targeting, Langmuir, 21, 5605, 10.1021/la047109v Laverman, 2001, In vivo applications of PEG liposomes: Unexpected observations, Crit Rev Ther Drug Carrier Syst, 18, 551, 10.1615/CritRevTherDrugCarrierSyst.v18.i6.40 Ho, 2003, Frictional properties of poly(MPC-co-BMA) phospholipid polymer for catheter applications, Biomaterials, 24, 5121, 10.1016/S0142-9612(03)00450-2 Iwasaki, 2002, Importance of a biofouling-resistant phospholipid polymer to create a heparinized blood-compatible surface, J Biomater Sci Polym Ed, 13, 323, 10.1163/156856202320176556 Iwasaki, 2002, Reduction of surface-induced inflammatory reaction on PLGA/MPC polymer blend, Biomaterials, 23, 3897, 10.1016/S0142-9612(02)00135-7 Konno, 2001, Preparation of nanoparticles composed with bioinspired 2-methacryloyloxyethyl phosphorylcholine polymer, Biomaterials, 22, 1883, 10.1016/S0142-9612(00)00373-2 Lewis, 2006, PC Technology as a platform for drug delivery: from combination to conjugation, Expert Opin Drug Deliv, 3, 289, 10.1517/17425247.3.2.289 Pincus, 1991, Colloid stabilization with grafted polyelectrolytes, Macromol, 24, 2912, 10.1021/ma00010a043 Finsinger, 2000, Protective copolymers for nonviral gene vectors: Synthesis, vector characterization and application in gene delivery, Gene Ther, 7, 1183, 10.1038/sj.gt.3301227 Dash, 1999, Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery, Gene Ther, 6, 643, 10.1038/sj.gt.3300843 Wiethoff, 2001, The potential role of proteoglycans in cationic lipid-mediated gene delivery. Studies of the interacttion of cationic lipid-DNA complexes with model glycosaminoglycans, J Biol Chem, 276, 32806, 10.1074/jbc.M007940200 Chittimalla, 2005, Monomolecular DNA nanoparticles for intravenous delivery of genes, J Am Chem Soc, 127, 11436, 10.1021/ja0522332 Prokop, 2002, Water-based nanoparticulate polymeric system for protein delivery, Biotechnol Bioeng, 75, 228, 10.1002/bit.10025 Prokop, 2002, Hydrogel-based colloidal polymeric system for protein and drug delivery: Physical and chemical characterization, permeability control and applications, Advan Polymer Sci, 160, 119, 10.1007/3-540-45362-8_3 Zelikin, 2003, Competitive reactions in solutions of poly-L-histidine, calf thymus DNA, and synthetic polyanions: Determining the binding constants of polyelectrolytes, J Am Chem Soc, 125, 13693, 10.1021/ja036387y Oupicky, 2002, Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation, Mol Ther, 5, 463, 10.1006/mthe.2002.0568 Ferrari, 2005, Nanovector therapeutics, Curr Opin Chem Biol, 9, 343, 10.1016/j.cbpa.2005.06.001 Decuzzi, 2005, A theoretical model for the margination of particles within blood vessels, Ann Biomed Eng, 33, 179, 10.1007/s10439-005-8976-5 Zeng, 2005, Clay-based polymer nanocomposites: Research and commercial development, J Nanosci Nanotechnol, 5, 1574, 10.1166/jnn.2005.411 Roser, 1998, Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats, Eur J Pharm Biopharm, 46, 255, 10.1016/S0939-6411(98)00038-1 Yang, 2002, Preparation and characterization of camptothecin solid lipid nanoparticles, Drug Dev Ind Pharm, 28, 265, 10.1081/DDC-120002842 Furumoto, 2004, Hepatic uptake of negatively charged particles in rats: Possible involvement of serum proteins in recognition by scavenger receptor, J Control Release, 97, 133, 10.1016/j.jconrel.2004.03.004 Eichhorn, 2004, Protamine enhances uptake of cationic liposomes in angiogenic microvessels, Angiogenesis, 7, 133, 10.1007/s10456-004-1428-2 Takagi, 2002, Effect of co-administration of cationic macromolecules on the in vivo disposition and in situ renal disposition characteristics of rhIL-11, Drug Metab Pharmacokinet, 17, 136, 10.2133/dmpk.17.136 Stacy, 2004, Radiation-guided drug delivery systems, Expert Rev Anticancer Ther, 4, 283, 10.1586/14737140.4.2.283 O'Neal, 2004, Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles, Cancer Lett, 209, 171, 10.1016/j.canlet.2004.02.004 Roy, 2003, Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug-carrier system for photodynamic therapy, J Am Chem Soc, 125, 7860, 10.1021/ja0343095 Oyewumi, 2002, Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy, Bioconjug Chem, 13, 1328, 10.1021/bc025560x Bergey, 2002, DC magnetic filed induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro, Biomed Microdev, 4, 293, 10.1023/A:1020906307053 Ishii, 2003, Chaperonin-mediated stabilization and ATP-triggered release of semiconductor nanoparticles, Nature, 423, 628, 10.1038/nature01663 Duncan, 2003, The dawning era of polymer therapeutics, Nat Rev Drug Discov, 2, 347, 10.1038/nrd1088 McLoughlin, 2005, TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long-term follow-up, Ann Surg Oncol, 12, 825, 10.1245/ASO.2005.03.023 Triggle, 2000, Hijacked receptors, Pharm Acta Helv, 74, 287, 10.1016/S0031-6865(99)00054-0 Juillerat-Jeanneret, 2006, Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail, Med Res Rev, 27, 574, 10.1002/med.20086 Parveen, 2006, Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs, Clin Pharmacokinet, 45, 965, 10.2165/00003088-200645100-00002 Vyas, 2001, Ligand-receptor-mediated drug delivery: An emerging paradigm in cellular drug targeting, Crit Rev Ther Drug Carrier Syst, 18, 1, 10.1615/CritRevTherDrugCarrierSyst.v18.i1.10 Veronese, 2002, Bioconjugation and biodistribution, 411 Nobs, 2004, Current methods for attaching targeting ligands to liposomes and nanoparticles, J Pharm Sci, 93, 1980, 10.1002/jps.20098 Khandare, 2006, Polymer-drug conjugates: Progress in polymeric prodrugs, Progr Polymer Sci, 31, 359, 10.1016/j.progpolymsci.2005.09.004 Haag, 2006, Polymer therapeutics: Concepts and applications, Angew Chem Int Ed Engl, 45, 1198, 10.1002/anie.200502113 Torchilin, 2006, Recent approaches to intracellular delivery of drugs and DNA and organelle targeting, Annu Rev Biomed Eng, 8, 343, 10.1146/annurev.bioeng.8.061505.095735 Soni, 2005, Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil, J Drug Target, 13, 245, 10.1080/10611860500107401 Kakudo, 2004, Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: An artificial viral-like delivery system, Biochem, 43, 5618, 10.1021/bi035802w Hatakeyama, 2004, Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo, Int J Pharm, 281, 25, 10.1016/j.ijpharm.2004.05.025 Liang, 2005, Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells, J Control Release, 105, 213, 10.1016/j.jconrel.2005.03.021 Managit, 2005, Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes, J Pharm Sci, 94, 2266, 10.1002/jps.20443 Adachi, 1997, Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain, Nucleic Acids Res, 25, 3135, 10.1093/nar/25.15.3135 Chiu, 2006, Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes, Anticancer Res, 26, 1049 Sonvico, 2005, Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments, Bioconjug Chem, 16, 1181, 10.1021/bc050050z Harvie, 2003, Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD motifs, J Liposome Res, 13, 231, 10.1081/LPR-120026389 Rejman, 2006, Gene transfer by means of lipo- and polyplexes: Role of clathrin and caveolae-mediated endocytosis, J Liposome Res, 16, 237, 10.1080/08982100600848819 Saul, 2006, A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers, J Control Release, 114, 277, 10.1016/j.jconrel.2006.05.028 Huang, 2004, Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor, Cancer Res, 64, 5355, 10.1158/0008-5472.CAN-04-0562 Caplan, 2005, Targeting drugs to combinations of receptors: A modeling analysis of potential specificity, Ann Biomed Eng, 33, 1113, 10.1007/s10439-005-5779-1 van Nieuw Amerongen, 2002, Targets for pharmacological intervention of endothelial hyperpermeability and barrier function, Vascul Pharmacol, 39, 257, 10.1016/S1537-1891(03)00014-4 Yuan, 1995, Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size, Cancer Res, 55, 3752 Yuan, 1994, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res, 54, 3352 Koukourakis, 1999, Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer, J Clin Oncol, 17, 3512, 10.1200/JCO.1999.17.11.3512 Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin Cancer Res, 7, 243 Veldman, 2005, Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin, J Pharmacol Exp Ther, 315, 704, 10.1124/jpet.105.087486 Gabizon, 2002, Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes, Cancer Res, 52, 891 Moase, 2001, Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer, Biochim Biophys Acta, 1510, 43, 10.1016/S0005-2736(00)00334-5 Minko, 2004, Molecular targeting of drug delivery systems to cancer, Curr Drug Targets, 5, 389, 10.2174/1389450043345443 Tanaka, 2003, Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model, Clin Endocrinol (Oxf), 59, 734, 10.1046/j.1365-2265.2003.01915.x Vannucci, 2003, Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo, Int J Oncol, 23, 285 Salama, 2006, Tight junction modulation and its relationship to drug delivery, Adv Drug Deliv Rev, 58, 15, 10.1016/j.addr.2006.01.003 Ishida, 2006, Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection, J Control Release, 115, 251, 10.1016/j.jconrel.2006.08.017 Ishida, 2006, Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes, J Control Release, 115, 243, 10.1016/j.jconrel.2006.08.001 O'Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann Oncol, 15, 440, 10.1093/annonc/mdh097 Sands, 2006, Gene therapy for lysosomal storage diseases, Mol Ther, 13, 839, 10.1016/j.ymthe.2006.01.006 Ramaekers, 2004, The cytoskeleton and disease, J Pathol, 204, 351, 10.1002/path.1665 Campbell, 2001, Caveolae and the caveolins in human disease, Adv Drug Deliv Rev, 49, 325, 10.1016/S0169-409X(01)00145-4 Panyam, 2002, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery, FASEB J, 16, 1217, 10.1096/fj.02-0088com Murphy, 2000, Drug delivery to mitochondria: The key to mitochondrial medicine, Adv Drug Deliv Rev, 41, 235, 10.1016/S0169-409X(99)00069-1 Holcik, 2004, Targeting endogenous inhibitors of apoptosis for treatment of cancer, stroke and multiple sclerosis, Expert Opin Ther Targets, 8, 241, 10.1517/14728222.8.3.241 Rothbard, 2005, Adaptive translocation: The role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells, Adv Drug Deliv Rev, 57, 495, 10.1016/j.addr.2004.10.003 Holt, 1988, Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies, Nature, 331, 717, 10.1038/331717a0 Simoes, 1998, Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides, Gene Ther, 5, 955, 10.1038/sj.gt.3300674 Tachibana, 1998, Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking, Biochem Biophys Res Commun, 251, 538, 10.1006/bbrc.1998.9460 Mendoza, 2005, Anti-tumor chemotherapy utilizing peptide-based approaches-apoptotic pathways, kinases, and proteasome as targets, Arch Immunol Ther Exp (Warsz), 53, 47 Shadidi, 2003, Selective targeting of cancer cells using synthetic peptides, Drug Resist Updat, 6, 363, 10.1016/j.drup.2003.11.002 Pawar, 2004, Intravenous and regional paclitaxel formulations, Curr Med Chem, 11, 397, 10.2174/0929867043455981 Goldberg, 2002, Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery, J Pharm Pharmacol, 54, 159, 10.1211/0022357021778268 Bogdanov, 1997, A long-circulating co-polymer in “passive targeting” to solid tumors, J Drug Target, 4, 321, 10.3109/10611869708995848 Brigger, 2002, Nanoparticles in cancer therapy and diagnosis, Adv Drug Deliv Rev, 54, 631, 10.1016/S0169-409X(02)00044-3 Némati, 1996, Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer, Int J Pharm, 138, 237, 10.1016/0378-5173(96)04559-0 Vauthier, 2003, Drug delivery to resistant tumors: The potential of poly(alkyl cyanoacrylate) nanoparticles, J Control Release, 93, 151, 10.1016/j.jconrel.2003.08.005 Jain, 1989, Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies, J Natl Cancer Inst, 81, 570, 10.1093/jnci/81.8.570 Jain, 1996, Delivery of molecular medicine to solid tumors, Science, 271, 1079, 10.1126/science.271.5252.1079 Jang, 2003, Drug delivery and transport to solid tumors, Pharm Res, 20, 1337, 10.1023/A:1025785505977 Feron, 2004, Targeting the tumor vascular compartment to improve conventional cancer therapy, Trends Pharmacol Sci, 25, 536, 10.1016/j.tips.2004.08.008 Alessi, 2004, Molecular targeting of angiogenesis, Biochim Biophys Acta, 1654, 39 Bocci, 2003, Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy, Proc Natl Acad Sci USA, 100, 12917, 10.1073/pnas.2135406100 Sun, 2007, The effects of lipiodol-hydroxyapatite nanoparticle on apoptosis, proliferation, and angiogenesis in hepatic tumor: Experiment with rabbits, Zhonghua Yi Xue Za Zhi, 87, 409 Stampfl, 2007, Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part II: Liver, Cardiovasc Intervent Radiol, 30, 462, 10.1007/s00270-005-0350-3 Cegnar, 2005, Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours, Expert Opin Biol Ther, 5, 1557, 10.1517/14712598.5.12.1557 Marcucci, 2004, Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress, Drug Discov Today, 9, 219, 10.1016/S1359-6446(03)02988-X Nori, 2005, Intracellular targeting of polymer-bound drugs for cancer chemotherapy, Adv Drug Deliv Rev, 57, 609, 10.1016/j.addr.2004.10.006 Seymour, 1992, Passive tumor targeting of soluble macromolecules and drug conjugates, Crit Rev Ther Drug Carrier Syst, 9, 135 Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562 Green, 1998, Polyethylene particles of a ‘critical size’ are necessary for the induction of cytokines by macrophages in vitro, Biomaterials, 19, 2297, 10.1016/S0142-9612(98)00140-9 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Kwon, 2005, Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to alpha v beta 3 receptor expressed in Kaposi's sarcoma, Mol Imaging, 4, 75, 10.1162/15353500200505103 Stoldt, 1997, Pretargeting strategies for radio-immunoguided tumour localisation and therapy, Eur J Cancer, 33, 186, 10.1016/S0959-8049(96)00477-7 Sharkey, 2005, Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody, Nat Med, 11, 1250, 10.1038/nm1322 Meredith, 2006, Pretargeted radioimmunotherapy, Int J Radiat Oncol Biol Phys, 66, S57, 10.1016/j.ijrobp.2006.04.058 Nobs, 2006, Biodegradable nanoparticles for direct or two-step tumor immunotargeting, Bioconjug Chem, 17, 139, 10.1021/bc050137k Hilgenbrink, 2005, Folate receptor-mediated drug targeting: From therapeutics to diagnostics, J Pharm Sci, 94, 2135, 10.1002/jps.20457 Lee, 1996, Measurement of endosome pH following folate receptor-mediated endocytosis, Biochim Biophys Acta, 1312, 237, 10.1016/0167-4889(96)00041-9 Turek, 1993, Endocytosis of folate-protein conjugates: Ultrastructural localization in KB cells, J Cell Sci, 106, 423, 10.1242/jcs.106.1.423 Line, 2005, Targeting tumor angiogenesis: Comparison of peptide and polymer-peptide conjugates, J Nucl Med, 46, 1552 Mitra, 2006, Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy, Nucl Med Biol, 33, 43, 10.1016/j.nucmedbio.2005.09.005 Kircheis, 2002, Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity, Cancer Gene Ther, 9, 673, 10.1038/sj.cgt.7700487 Yu, 2004, A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene, Gene Ther, 11, 1434, 10.1038/sj.gt.3302304 Gunther, 2005, Specific targets in tumor tissue for the delivery of therapeutic genes, Curr Med Chem Anticancer Agents, 5, 157, 10.2174/1568011053174855 Baish, 1996, Role of tumor vascular architecture in nutrient and drug delivery: An invasion percolation-based network model, Microvasc Res, 51, 327, 10.1006/mvre.1996.0031 Jain, 2005, Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Kano, 2007, Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling, Proc Natl Acad Sci USA, 104, 3460, 10.1073/pnas.0611660104 Lutsiak, 2006, Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses, J Pharm Pharmacol, 58, 739, 10.1211/jpp.58.6.0004 Kocbek, 2007, Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, J Control Release, 120, 18, 10.1016/j.jconrel.2007.03.012 Huang, 2007, Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor, Biomacromol, 8, 1607, 10.1021/bm061211k Luu, 2003, Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers, J Control Release, 89, 341, 10.1016/S0168-3659(03)00097-X Yu, 2007, Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin, J Drug Target, 15, 279, 10.1080/10611860701357235 Zhang, 2006, Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FR GD2, J Nucl Med, 47, 113 Nafee, 2007, Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides, Nanomed, 3, 173, 10.1016/j.nano.2007.03.006 Ojeda, 2007, Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines, Carbohydr Res, 342, 448, 10.1016/j.carres.2006.11.018 Lecaroz, 2006, Nanocarriers with gentamicin to treat intracellular pathogens, J Nanosci Nanotechnol, 6, 3296, 10.1166/jnn.2006.478 Stephens, 2003, Antisense oligonucleotide therapy in cancer, Curr Opin Mol Ther, 5, 118 Ala-aho, 2004, Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo, Oncogene, 23, 5111, 10.1038/sj.onc.1207678 Silverman, 2005, In vitro selection, characterization, and application of deoxyribozymes that cleave RNA, Nucleic Acids Res, 33, 6151, 10.1093/nar/gki930 Fang, 2001, Molecular aptamer for real-time oncoprotein platelet-derived growth factor monitoring by fluorescence anisotropy, Anal Chem, 73, 5752, 10.1021/ac010703e Nimjee, 2005, Aptamers: An emerging class of therapeutics, Annu Rev Med, 56, 555, 10.1146/annurev.med.56.062904.144915 Sumimoto, 2004, Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference, Oncogene, 23, 6031, 10.1038/sj.onc.1207812 Ayyagari, 2006, Long-circulating liposomal contrast agents for magnetic resonance imaging, Magn Reson Med, 55, 1023, 10.1002/mrm.20846 Wu, 2003, Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots, Nat Biotechnol, 21, 41, 10.1038/nbt764 Larson, 2003, Water-soluble quantum dots for multiphoton fluorescence imaging in vivo, Science, 300, 1434, 10.1126/science.1083780 Kim, 2004, Adaptation of inorganic quantum dots for stable molecular beacons, Sens Actuators B Chem, 102, 315, 10.1016/j.snb.2004.04.107 Kim, 2004, Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping, Nat Biotechnol, 22, 93, 10.1038/nbt920 Derfus, 2004, Probing the cytotoxicity of semiconductor quantum dots, Nano Lett, 4, 11, 10.1021/nl0347334 Portney, 2006, Nano-oncology: Drug delivery, imaging, and sensing, Anal Bioanal Chem, 384, 620, 10.1007/s00216-005-0247-7 Kobayashi, 2005, Nano-sized MRI contrast agents with dendrimer cores, Adv Drug Deliv Rev, 57, 2271, 10.1016/j.addr.2005.09.016 Kawata, 2004, Near-field optics and spectroscopy for molecular nano-imaging, Sci Prog, 87, 25, 10.3184/003685004783238580 Quaresima, 1998, Identification and quantification of intrinsic optical contrast for near-infrared mammography, Photochem Photobiol, 67, 4, 10.1111/j.1751-1097.1998.tb05159.x Ntziachristos, 2002, In vivo tomographic imaging of near-infrared fluorescent probes, Mol Imaging, 1, 82, 10.1162/153535002320162732 Hirsch, 2003, Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance, Proc Natl Acad Sci USA, 100, 13549, 10.1073/pnas.2232479100 Ntziachristos, 2002, Would near-infrared fluorescence signals propagate through large human oragns for clinical studies?, Optics Lett, 27, 333, 10.1364/OL.27.000333 Ntziachristos, 2002, Fluorescence molecular tomography resolves protease activity in vivo, Nat Med, 8, 757, 10.1038/nm729 Citrin, 2004, In vivo tumor imaging in mice with near-infrared labeled endostatin, Mol Cancer Ther, 3, 481 Cheng, 2005, Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice, Bioconjug Chem, 16, 1433, 10.1021/bc0501698 Ye, 2006, Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors, J Med Chem, 49, 2268, 10.1021/jm050947h Kelly, 2006, In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging, Mol Imaging Biol, 8, 201, 10.1007/s11307-006-0043-6 Montet, 2006, Multivalent effects of RGD peptides obtained by nanoparticle display, J Med Chem, 49, 6087, 10.1021/jm060515m Kobayashi, 2001, Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents, J Magn Reson Imaging, 14, 705, 10.1002/jmri.10025 Kobayashi, 2004, Dendrimer-based nanosized MRI contrast agents, Curr Pharm Biotechnol, 5, 539, 10.2174/1389201043376571 Lewis, 2006, Viral nanoparticles as tools for intravital vascular imaging, Nat Med, 12, 354, 10.1038/nm1368 Voisin, 2007, Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging, Bioconjug Chem, 18, 1053, 10.1021/bc060269t Bertorelle, 2006, Fluorescence-modified superparamagnetic nanoparticles: Intracellular uptake and use in cellular imaging, Langmuir, 22, 5385, 10.1021/la052710u Sosnovik, 2005, Magnetic resonance and fluorescence based molecular imaging technologies, Prog Drug Res, 62, 83, 10.1007/3-7643-7426-8_3 Bradbury, 2005, Molecular MR imaging in oncology, Magn Reson Imaging Clin N Am, 13, 225, 10.1016/j.mric.2005.03.008 Neves, 2006, Assessing responses to cancer therapy using molecular imaging, Biochim Biophys Acta, 766, 242 Desai, 2006, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel, Clin Cancer Res, 12, 1317, 10.1158/1078-0432.CCR-05-1634 John, 2001, Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung, J Physiol, 533, 547, 10.1111/j.1469-7793.2001.0547a.x Kharb, 2006, Nanoparticle technology for the delivery of poorly water-soluble drugs, Pharm Technol, 30, 82 Muller, 2001, Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future, Adv Drug Deliv Rev, 47, 3, 10.1016/S0169-409X(00)00118-6 Frazza, 1971, A new absorbable suture, J Biomed Mater Res, 1, 43, 10.1002/jbm.820050207 Gilding, 1981, Biodegradable polymers, 209 Vert, 1994, Biodegradation of PLA/GA polymers: Increasing complexity, Biomaterials, 15, 1209, 10.1016/0142-9612(94)90271-2 Bazile, 1992, Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats, Biomaterials, 13, 1093, 10.1016/0142-9612(92)90142-B Venier-Julienne, 1996, Preparation, purification and morphology of polymeric nanoparticles as drug carriers, Pharm Acta Helv, 71, 121, 10.1016/0031-6865(95)00059-3 Bala, 2004, PLGA nanoparticles in drug delivery: The state of the art, Crit Rev Ther Drug Carrier Syst, 21, 387, 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20 Couvreur, 1979, Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: Preparation, morphological and sorptive properties, J Pharm Pharmacol, 31, 331, 10.1111/j.2042-7158.1979.tb13510.x Lenaerts, 1984, Degradation of poly (isobutyl cyanoacrylate) nanoparticles, Biomaterials, 5, 65, 10.1016/0142-9612(84)90002-4 Vauthier, 2003, Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications, Adv Drug Deliv Rev, 55, 519, 10.1016/S0169-409X(03)00041-3 Merle, 2006, Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug® (DT) for patients with advanced hepatocellular carcinoma (HCC), J Clin Virol, 36, 179, 10.1016/S1386-6532(06)80558-5 Carlesso, 2003, Nanoparticulate system for efficient gene transfer into refractory cell targets, Biomacromol, 6, 1185, 10.1021/bm0492531 (b) Anonymous:http://www.bioalliancepharma.com/clinicaltrials.asp. Kattan, 1992, Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles, Invest New Drugs, 10, 191, 10.1007/BF00877245 Prokop, 2000, Water-based nanoparticulate polymeric system for protein delivery: Permeability control and vaccine application, Biotechnol Bioeng, 78, 459, 10.1002/bit.1200 Fernandez-Urrusuno, 1999, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm Res, 16, 1576, 10.1023/A:1018908705446 Calvo, 1997, Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers, J Appl Pol Sci, 63, 125, 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 Pinto Reis, 2006, Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles, Nanomed Nanotechnol Biol Med, 2, 8, 10.1016/j.nano.2005.12.003 Kataoka, 2001, Block copolymer micelles for drug delivery: Design, characterization and biological significance, Adv Drug Deliv Rev, 47, 113, 10.1016/S0169-409X(00)00124-1 Otsuka, 2003, PEGylated nanoparticles for biological and pharmaceutical applications, Adv Drug Deliv Rev, 55, 403, 10.1016/S0169-409X(02)00226-0 Oishi, 2005, Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages, Chembiochem, 6, 718, 10.1002/cbic.200400334 Nakanishi, 2001, Development of the polymer micelle carrier system for doxorubicin, J Control Release, 74, 295, 10.1016/S0168-3659(01)00341-8 Bae, 2005, Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy, Bioconjug Chem, 16, 122, 10.1021/bc0498166 Uchino, 2005, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats, Br J Cancer, 93, 678, 10.1038/sj.bjc.6602772 Hamaguchi, 2005, NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel, Br J Cancer, 92, 1240, 10.1038/sj.bjc.6602479 Lavasanifar, 2002, Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery, Adv Drug Deliv Rev, 54, 169, 10.1016/S0169-409X(02)00015-7 Liu, 2005, Multilayer microcapsules as anti-cancer drug delivery vehicle: Deposition, sustained release, and in vitro bioactivity, Macromol Biosci, 5, 1209, 10.1002/mabi.200500176 Ai, 2005, Interactions between self-assembled polyelectrolyte shells and tumor cells, J Biomed Mater Res A, 73, 303, 10.1002/jbm.a.30289 Berg, 2006, Controlled drug release from porous polyelectrolyte multilayers, Biomacromolecules, 7, 357, 10.1021/bm050174e Garza, 2005, Polyelectrolyte multilayers and degradable polymer layers as multicompartment films, Langmuir, 21, 12372, 10.1021/la051465b Zhang, 2006, Structure/property relationships in erodible multilayered films: Influence of polycation structure on erosion profiles and the release of anionic polyelectrolytes, Langmuir, 22, 239, 10.1021/la052360b Haynie, 2005, Polypeptide multilayer films, Biomacromol, 6, 2895, 10.1021/bm050525p Morgan, 2002, Heterogeneously functionalized dendrimers, Curr Opin Drug Discov Devel, 5, 966 Majoros, 2005, Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy, J Med Chem, 48, 5892, 10.1021/jm0401863 Bhadra, 2003, A PEGylated dendritic nanoparticulate carrier of fluorouracil, Int J Pharm, 257, 111, 10.1016/S0378-5173(03)00132-7 Andre, 2004, Lanthanide(III) complexes of DOTA-glycoconjugates: A potential new class of lectin-mediated medical imaging agents, Chemistry, 10, 5804, 10.1002/chem.200400187 Khopade, 2004, Phase structures of a hydrated anionic phospholipid composition containing cationic dendrimers and pegylated lipids, Langmuir, 20, 7368, 10.1021/la049682k Duncan, 2005, Dendrimer biocompatibility and toxicity, Adv Drug Deliv Rev, 57, 2215, 10.1016/j.addr.2005.09.019 Majoros, 2006, PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality, Biomacromol, 7, 572, 10.1021/bm0506142 Jiang, 2005, PL7013 gel as a topical microbicide for prevention of vaginal transmission of SH IV89.6P in macaques, AIDS Res Hum Retroviruses, 21, 207, 10.1089/aid.2005.21.207 Blume, 1990, Liposomes for the sustained drug release in vivo, Biochim Biophys Acta, 1029, 91, 10.1016/0005-2736(90)90440-Y Crosasso, 2000, Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes, J Control Release, 63, 19, 10.1016/S0168-3659(99)00166-2 Cattel, 2004, From conventional to stealth liposomes: A new frontier in cancer chemotherapy, J Chemother, 16, 94, 10.1179/joc.2004.16.Supplement-1.94 Ishida, 1999, Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice, Int J Pharm, 190, 49, 10.1016/S0378-5173(99)00256-2 Bakouche, 1990, Antigen presentation by liposomes bearing class II MHC and membrane IL-1, Yale J Biol Med, 63, 95 Fries, 1992, Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy, Proc Natl Acad Sci USA, 89, 358, 10.1073/pnas.89.1.358 Campos, 2003, Liposomal anthracyclines: Adjuvant and neoadjuvant therapy for breast cancer, Oncologist, 8, 10, 10.1634/theoncologist.8-suppl_2-10 Song, 2002, Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes, Biochim Biophys Acta, 1558, 1, 10.1016/S0005-2736(01)00399-6 Monck, 2000, Stabilized plasmid-lipid particles: Pharmacokinetics and plasmid delivery to distal tumors following intravenous injection, J Drug Target, 7, 439, 10.3109/10611860009102218 Kamps, 1999, Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: In vivo-in vitro differences, Biochem Biophys Res Commun, 256, 57, 10.1006/bbrc.1999.0290 Goyal, 2005, Liposomal drug delivery systems-clinical applications, Acta Pharm, 55, 1 Drummond, 2000, Current status of pH-sensitive liposomes in drug delivery, Prog Lipid Res, 39, 409, 10.1016/S0163-7827(00)00011-4 Ruponen, 1999, Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies, Biochim Biophys Acta, 1415, 331, 10.1016/S0005-2736(98)00199-0 Lee, 1992, Recognition of liposomes by cells: In vitro binding and en docytosis mediated by specific lipid headgroups and surface charge density, Biochim Biophys Acta, 1103, 185, 10.1016/0005-2736(92)90086-2 Bummer, 2004, Physical chemical considerations of lipid-based oral drug delivery–solid lipid nanoparticles, Crit Rev Ther Drug Carrier Syst, 21, 1, 10.1615/CritRevTherDrugCarrierSyst.v21.i1.10 Manjunath, 2005, Solid lipid nanoparticles as drug delivery systems, Methods Find Exp Clin Pharmacol, 27, 127, 10.1358/mf.2005.27.2.876286 Saupe, 2005, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Structural investigations on two different carrier systems, Biomed Mater Eng, 15, 393 Rensen, 2001, Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting, Adv Drug Deliv Rev, 47, 251, 10.1016/S0169-409X(01)00109-0 West, 2005, Reversible covalent chemistry in drug delivery, Curr Drug Discov Technol, 2, 123, 10.2174/1570163054866882 Miyamoto, 1990, Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro, Cancer Res, 50, 1571 St'astny, 1999, A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier, Eur J Cancer, 35, 459, 10.1016/S0959-8049(98)00373-6 Goren, 2000, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump, Clin Cancer Res, 6, 1949 Katragadda, 2005, Role of efflux pumps and metabolising enzymes in drug delivery, Expert Opin Drug Deliv, 2, 683, 10.1517/17425247.2.4.683 Mamot, 2003, Liposome-based approaches to overcome anticancer drug resistance, Drug Resist Updat, 6, 271, 10.1016/S1368-7646(03)00082-7 de Verdiere, 1997, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action, Br J Cancer, 76, 198, 10.1038/bjc.1997.362 Garcion, 2006, A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Mol Cancer Ther, 5, 1710, 10.1158/1535-7163.MCT-06-0289 Wong, 2006, A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells, Pharm Res, 23, 1574, 10.1007/s11095-006-0282-x Seymour, 2002, Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin, J Clin Oncol, 20, 1668, 10.1200/JCO.20.6.1668 Satchi-Fainaro, 2004, Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470, Nat Med, 10, 255, 10.1038/nm1002 Qiu, 2006, Polymer architecture and drug delivery, Pharm Res, 23, 1, 10.1007/s11095-005-9046-2 Zorko, 2005, Cell-penetrating peptides: Mechanism and kinetics of cargo delivery, Adv Drug Deliv Rev, 57, 529, 10.1016/j.addr.2004.10.010 Vives, 1997, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J Biol Chem, 272, 16010, 10.1074/jbc.272.25.16010 Gupta, 2005, Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides, Adv Drug Deliv Rev, 57, 637, 10.1016/j.addr.2004.10.007 Marty, 2004, Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes, Cell Mol Life Sci, 61, 1785, 10.1007/s00018-004-4166-0 Oehlke, 2005, Studies on the cellular uptake of substance P and lysine-rich, KLA-derived model peptides, J Mol Recognit, 18, 50, 10.1002/jmr.691 Nakase, 2004, Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement, Mol Ther, 10, 1011, 10.1016/j.ymthe.2004.08.010 Dokka, 1997, Cellular delivery of oligonucleotides by synthetic import peptide carrier, Pharm Res, 14, 1759, 10.1023/A:1012188014919 Fernandez-Carneado, 2005, Highly efficient, nonpeptidic oligoguanidinium vectors that selectively internalize into mitochondria, J Am Chem Soc, 127, 869, 10.1021/ja044006q Yanagishita, 1992, Cell surface heparan sulfate proteoglycans, J Biol Chem, 267, 9451, 10.1016/S0021-9258(19)50108-9 Sonvico, 2005, Metallic colloid nanotechnology, applications in diagnosis and therapeutics, Curr Pharm Des, 11, 2095, 10.2174/1381612054065738 Loo, 2005, Immunotargeted nanoshells for integrated cancer imaging and therapy, Nano Lett, 5, 709, 10.1021/nl050127s Martin, 2003, The emerging field of nanotube biotechnology, Nat Rev Drug Discov, 2, 29, 10.1038/nrd988 Kam, 2005, Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction, Proc Natl Acad Sci USA, 102, 11600, 10.1073/pnas.0502680102 Jain, 2005, Iron oxide nanoparticles for sustained delivery of anticancer agents, Mol Pharm, 2, 194, 10.1021/mp0500014 Maitra, 2005, Calcium phosphate nanoparticles: Second-generation nonviral vectors in gene therapy, Expert Rev Mol Diagn, 5, 893, 10.1586/14737159.5.6.893 Gemeinhart, 2005, Cellular fate of a modular DNA delivery system mediated by silica nanoparticles, Biotechnol Prog, 21, 532, 10.1021/bp049648w Klumpp, 2005, Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics, Biochim Biophys Acta, 1758, 404, 10.1016/j.bbamem.2005.10.008 Wang, 2004, Biodistribution of carbon single-wall carbon nanotubes in mice, J Nanosci Nanotechnol, 4, 1019, 10.1166/jnn.2004.146 Pantarotto, 2004, Functionalized carbon nanotubes for plasmid DNA gene delivery, Angew Chem Int Ed Engl, 43, 5242, 10.1002/anie.200460437 Bianco, 2004, Carbon nanotubes for the delivery of therapeutic molecules, Expert Opin Drug Deliv, 1, 57, 10.1517/17425247.1.1.57 Constancis, 1999, Macromolecular colloids of diblock poly(amino acids) that bind insulin, J Colloid Interface Sci, 217, 357, 10.1006/jcis.1999.6383 Nowak, 2003, Unusual salt stability in highly charged diblock co-polypeptide hydrogels, J Am Chem Soc, 125, 15666, 10.1021/ja0381050 Kreiss, 1999, Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency, Nucleic Acids Res, 27, 3792, 10.1093/nar/27.19.3792 Escriou, 2003, NLS bioconjugates for targeting therapeutic genes to the nucleus, Adv Drug Deliv Rev, 55, 295, 10.1016/S0169-409X(02)00184-9 Vacik, 1999, Cell-specific nuclear import of plasmid DNA, Gene Ther, 6, 1006, 10.1038/sj.gt.3300924 Lechardeur, 2002, Intracellular barriers to non-viral gene transfer, Curr Gene Ther, 2, 183, 10.2174/1566523024605609 Rosenberg, 2000, Human gene marker/therapy clinical protocols, Hum Gene Ther, 11, 919, 10.1089/10430340050015536 Dyer, 2000, Progress and potential for gene-based medicines, Mol Ther, 1, 213, 10.1006/mthe.2000.0044 Trubetskoy, 2003, Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery, Gene Ther, 10, 261, 10.1038/sj.gt.3301888 Sagara, 2002, A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes, J Control Release, 79, 271, 10.1016/S0168-3659(01)00555-7 Kichler, 2004, Gene transfer with modified polyethylenimines, J Gene Med, 6, S3, 10.1002/jgm.507 Simonson, 2005, Bioplex technology: Novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids, Curr Pharm Des, 11, 3671, 10.2174/138161205774580813 Piskin, 2004, Gene delivery: Intelligent but just at the beginning, J Biomater Sci Polym Ed, 15, 1181, 10.1163/1568562041753016 Brown, 2000, Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents, Bioconj Chem, 11, 880, 10.1021/bc000052d Cui, 2002, Plasmid DNA-entrapped nanoparticles engineered from microemulsion precursors: In vitro and in vivo evaluation, Bioconjug Chem, 13, 1319, 10.1021/bc0255586 Bozkir, 2004, Chitosan-DNA nanoparticles: Effect on DNA integrity, bacterial transformation and transfection efficiency, J Drug Target, 12, 281, 10.1080/10611860410001714162 Prabha, 2004, Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells, Mol Pharm, 1, 211, 10.1021/mp049970+ Haas, 2005, Preparation and characterization of chitosan and trimethyl-chitosan-modified poly-(epsilon-caprolactone) nanoparticles as DNA carriers, AAPS Pharm Sci Tech, 6, E22, 10.1208/pt060106 Banerjee, 2004, Novel hyperbranched dendron for gene transfer in vitro and in vivo, Bioconjug Chem, 15, 960, 10.1021/bc0342128 O'Brien, 2002, An improved method of preparing microcarriers for biolistic transfection, Brain Res Brain Res Protoc, 10, 12, 10.1016/S1385-299X(02)00175-7 Eming, 2004, Gene transfer in tissue repair: Status, challenges and future directions, Expert Opin Biol Ther, 4, 1373, 10.1517/14712598.4.9.1373 Roelvink, 1999, Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae, Science, 286, 1568, 10.1126/science.286.5444.1568 Lin, 2004, Oncolytic viral therapies, Cancer Gene Ther, 11, 643, 10.1038/sj.cgt.7700733 Mizuguchi, 1997, Cytoplasmic gene expression system enhances the efficiency of cationic liposome-mediated in vivo gene transfer into mouse brain, Biochem Biophys Res Commun, 234, 15, 10.1006/bbrc.1997.6568 Patil, 2005, DNA-based therapeutics and DNA delivery systems: A comprehensive review, AAPS J, 7, E61, 10.1208/aapsj070109 Irache, 2005, Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs, Mini Rev Med Chem, 5, 293, 10.2174/1389557053175335 Tousignant, 2000, Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice, Hum Gene Ther, 11, 2493, 10.1089/10430340050207984 Ruiz, 2001, A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis, Hum Gene Ther, 12, 751, 10.1089/104303401750148667 Verma, 1997, Gene therapy—Promises, problems and prospects, Nature, 389, 239, 10.1038/38410 Wiethoff, 2003, Barriers to nonviral gene delivery, J Pharm Sci, 92, 203, 10.1002/jps.10286 Wikswo, 2006, The engineering challenges of BioMEMS: The integration of microfluidics, micro- and nano-devices, models, and external control for systems biology, IEE Proc Nanobiotech, 153, 81, 10.1049/ip-nbt:20050045 Hummel, 1942 Prokop, 1982, Systems-analysis and synthesis in biology and biotechnology, Int J Gen Syst, 8, 7, 10.1080/03081078208934831 Rashevsky, 1962, Mathematical foundations of general biology, Ann N Y Acad Sci, 96, 1105 Miller, 1978 Papin, 2004, Topological analysis of mass-balanced signaling networks: A framework to obtain network properties including crosstalk, J Theor Biol, 227, 283, 10.1016/j.jtbi.2003.11.016 Papin, 2004, Comparison of network-based pathway analysis methods, Trends Biotechnol, 22, 400, 10.1016/j.tibtech.2004.06.010 Tyson, 2003, Sniffers, buzzers, toggles and blinkers: Dynamics of regulatory and signaling pathways in the cell, Curr Opin Cell Biol, 15, 221, 10.1016/S0955-0674(03)00017-6 Kholodenko, 2002, Untangling the wires: A strategy to trace functional interactions in signaling and gene networks, Proc Natl Acad Sci USA, 99, 15245, 10.1073/pnas.192442699 Kholodenko, 1997, Quantification of information transfer via cellular signal transduction pathways, FEBS Lett, 414, 430, 10.1016/S0014-5793(97)01018-1 Hornberg, 2006, Cancer: A systems biology disease, Biosystems, 83, 81, 10.1016/j.biosystems.2005.05.014 Radivoyevitch, 2006, On systems and control approaches to therapeutic gain, BMC Cancer, 6, 104, 10.1186/1471-2407-6-104 Ahmed, 2006, Multiscale modeling of macromolecular conformational changes combining concepts from rigidity and elastic network theory, Proteins, 63, 1038, 10.1002/prot.20907 Botta, 2002, Molecular modeling as a powerful technique for understanding small-large molecules interactions, Farmaco, 57, 153, 10.1016/S0014-827X(01)01184-3 Balakin, 2006, In silico approaches to prediction of aqueous and DMSO solubility of drug-like compounds: Trends, problems and solutions, Curr Med Chem, 13, 223, 10.2174/092986706775197917 Stenberg, 2002, Theoretical predictions of drug absorption in drug discovery and development, Clin Pharmacokinet, 41, 877, 10.2165/00003088-200241110-00005 Braccini, 1999, Conformational and configurational features of acidic polysaccharides and their interactions with calcium ions: A molecular modeling investigation, Carbohydr Res, 317, 119, 10.1016/S0008-6215(99)00062-2 Makabe, 2006, Atomic structures of peptide self-assembly mimics, Proc Natl Acad Sci USA, 103, 17753, 10.1073/pnas.0606690103 Tieleman, 2006, Computer simulations of transport through membranes: Passive diffusion, pores, channels and transporters, Clin Exp Pharmacol Physiol, 33, 893, 10.1111/j.1440-1681.2006.04461.x Kanjickal, 2004, Modeling of drug release from polymeric delivery systems–A review, Crit Rev Ther Drug Carrier Syst, 21, 345, 10.1615/CritRevTherDrugCarrierSyst.v21.i5.10 Sousa, 2006, Protein-ligand docking: Current status and future challenges, Proteins, 65, 15, 10.1002/prot.21082 Boscolo, 2005, A generalized framework for network component analysis, IEEE/ACM Trans Comput Biol Bioinform, 2, 289, 10.1109/TCBB.2005.47 Maeda, 2006, Regulatory dynamics of synthetic gene networks with positive feedback, J Mol Biol, 359, 1107, 10.1016/j.jmb.2006.03.064 Teusink, 2000, Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry, Eur J Biochem, 267, 5313, 10.1046/j.1432-1327.2000.01527.x Oliveira, 2003, A computational model for the identification of biochemical pathways in the krebs cycle, J Comput Biol, 10, 57, 10.1089/106652703763255679 Namjoshi, 2003, Unveiling steady-state multiplicity in hybridoma cultures: The cybernetic approach, Biotechnol Bioeng, 81, 80, 10.1002/bit.10447 Uygun, 2006, Investigation of metabolic objectives in cultured hepatocytes, Biotechnol Bioeng, 97, 622, 10.1002/bit.21237 Balaban, 2006, Modeling mitochondrial function, Am J Physiol Cell Physiol, 291, C1107, 10.1152/ajpcell.00223.2006 Schwartz, 2006, Quantitative elementary mode analysis of metabolic pathways: The example of yeast glycolysis, BMC Bioinformatics, 7, 186, 10.1186/1471-2105-7-186 Clarke, 2006, Stem cells and cancer: Two faces of eve, Cell, 124, 1111, 10.1016/j.cell.2006.03.011 Ganguly, 2006, Mathematical model for the cancer stem cell hypothesis, Cell Prolif, 39, 3, 10.1111/j.1365-2184.2006.00369.x Dasika, 2006, A computational framework for the topological analysis and targeted disruption of signal transduction networks, Biophys J, 91, 382, 10.1529/biophysj.105.069724 Geho, 2005, Modeling of protein signaling networks in clinical proteomics, Cold Spring Harb Symp Quant Biol, 70, 517, 10.1101/sqb.2005.70.022 Orton, 2005, Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway, Biochem J, 392, 249, 10.1042/BJ20050908 Schoeberl, 2002, Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors, Nat Biotechnol, 20, 370, 10.1038/nbt0402-370 Sasagawa, 2005, Prediction and validation of the distinct dynamics of transient and sustained ERK activation, Nat Cell Biol, 7, 365, 10.1038/ncb1233 Hua, 2005, Integrated mechanistic and data-driven modelling for multivariate analysis of signalling pathways, J R Soc Interface, 3, 515, 10.1098/rsif.2005.0109 Klamt, 2006, A methodology for the structural and functional analysis of signaling and regulatory networks, BMC Bioinformatics, 7, 56, 10.1186/1471-2105-7-56 Zhu, 2006, Brownian diffusion and surface kinetics of liposome and viral particle uptake by human lung cancer cells in-vitro, Ann Biomed Eng, 34, 1573, 10.1007/s10439-006-9158-9 Lund, 1990, Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization, J Biol Chem, 265, 15713, 10.1016/S0021-9258(18)55456-9 Wustner, 2006, Quantification of polarized trafficking of transferrin and comparison with bulk membrane transport in hepatic cells, Biochem J, 400, 267, 10.1042/BJ20060626 Wustner, 2005, Mathematical analysis of hepatic high density lipoprotein transport based on quantitative imaging data, J Biol Chem, 280, 6766, 10.1074/jbc.M413238200 Heckman, 2001, Mathematical modeling of marker influx and efflux in cells, Bull Math Biol, 63, 431, 10.1006/bulm.2001.0216 Enderling, 2006, Mathematical modelling of radiotherapy strategies for early breast cancer, J Theor Biol, 241, 158, 10.1016/j.jtbi.2005.11.015 Ribba, 2006, A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies, Theor Biol Med Model, 243, 532, 10.1016/j.jtbi.2006.07.013 Sinek, 2006, Mathematical and computational modeling: Towards the development and application of nanodevices for drug delivery Wein, 2002, A mathematical model of the impact of infused targeted cytotoxic agents on brain tumours: Implications for detection, design and delivery, Cell Prolif, 35, 343, 10.1046/j.1365-2184.2002.00246.x Levasseur, 1998, Modeling of the time-dependency of in vitro drug cytotoxicity and resistance, Cancer Res, 58, 5749 Fitzgerald, 2006, Systems biology and combination therapy in the quest for clinical efficacy, Nat Chem Biol, 2, 458, 10.1038/nchembio817 Araujo, 2005, A mathematical model of combination therapy using the EGFR signaling network, Biosystems, 80, 57, 10.1016/j.biosystems.2004.10.002 Ramsay, 2005, The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations, Curr Drug Deliv, 2, 341, 10.2174/156720105774370294 Novak, 2004, A model for restriction point control of the mammalian cell cycle, J Theor Biol, 230, 563, 10.1016/j.jtbi.2004.04.039 Frieboes, 2006, An integrated computational/experimental model of tumor invasion, Cancer Res, 66, 1597, 10.1158/0008-5472.CAN-05-3166 Michor, 2006, Stochastic dynamics of metastasis formation, J Theor Biol, 240, 521, 10.1016/j.jtbi.2005.10.021 Colijn, 2005, A mathematical model of hematopoiesis–I. Periodic chronic myelogenous leukemia, J Theor Biol, 237, 117, 10.1016/j.jtbi.2005.03.033 McDougall, 2006, Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategies, J Theor Biol, 241, 564, 10.1016/j.jtbi.2005.12.022 Chaplain, 2004, Mathematical modelling of tumour-induced angiogenesis: Network growth and structure, Cancer Treat Res, 117, 51, 10.1007/978-1-4419-8871-3_3 Spinelli, 2006, Modelling the balance between quiescence and cell death in normal and tumour cell populations, Math Biosci, 202, 349, 10.1016/j.mbs.2006.03.016 Bentele, 2004, Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis, J Cell Biol, 166, 839, 10.1083/jcb.200404158 Anderson, 2006, Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment, Cell, 127, 905, 10.1016/j.cell.2006.09.042 Sinek, 2004, Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles, Biomed Microdevices, 6, 297, 10.1023/B:BMMD.0000048562.29657.64 Furlani, 2006, Analytical model of magnetic nanoparticle transport and capture in the microvasculature, Phys Rev E Stat Nonlin Soft Matter Phys, 73, 061919, 10.1103/PhysRevE.73.061919 Ghaghada, 2005, Folate targeting of drug carriers: A mathematical model, J Control Release, 104, 113, 10.1016/j.jconrel.2005.01.012 Chappell, 1991, Optimal tumor targeting by antibodies: Development of a mathematical model, J Pharmacokinet Biopharm, 19, 227, 10.1007/BF01073870 He, 2006, A numerical coupling model to analyze the blood flow, temperature, and oxygen transport in human breast tumor under laser irradiation, Comput Biol Med, 36, 1336, 10.1016/j.compbiomed.2005.08.004 Decuzzi, 2006, The effective dispersion of nanovectors within the tumor microvasculature, Ann Biomed Eng, 34, 633, 10.1007/s10439-005-9072-6 Graff, 2003, Theoretical analysis of antibody targeting of tumor spheroids: Importance of dosage for penetration, and affinity for retention, Cancer Res, 63, 1288 Maseide, 2000, Mathematical modeling of chronical hypoxia in tumors considering potential doubling time and hypoxic cell lifetime, Radiother Oncol, 54, 171, 10.1016/S0167-8140(99)00154-1 Reddy, 2006, A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles, J Appl Physiol, 101, 1162, 10.1152/japplphysiol.00389.2006 Bondareva, 1995, A non-linear mathematical model for the in vivo evaluation of the RES phagocytic function, Medinfo, 8, 1091 Wang, 2003, A simplified and comprehensive computational model to study the behavior of T cell populations in the thymus during normal maturation and in infection with mouse moloney leukemiavirus, In Vivo, 17, 225 Baxter, 1991, Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution, Microvasc Res, 41, 252, 10.1016/0026-2862(91)90026-8 Stachowska-Pietka, 2006, Distributed model of peritoneal fluid absorption, Am J Physiol Heart Circ Physiol, 291, H1862, 10.1152/ajpheart.01320.2005 Green, 2001, Mathematical model of antibody targeting: Important parameters defined using clinical data, Phys Med Biol, 46, 1679, 10.1088/0031-9155/46/6/307 Yates, 2006, Structural identifiability of physiologically based pharmacokinetic models, J Pharmacokinet Pharmacodyn, 33, 421, 10.1007/s10928-006-9011-7 Pond, 1984, First-pass elimination. Basic concepts and clinical consequences, Clin Pharmacokinet, 9, 1, 10.2165/00003088-198409010-00001 Mano, 1997, Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: comparison between in vitro and in vivo disposition, J Pharmacol Exp Ther, 283, 391 Varner, 2005, Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT), Syst Biol (Stevenage), 152, 291, 10.1049/ip-syb:20050047 Christopher, 2004, Data-driven computer simulation of human cancer cell, Ann N Y Acad Sci, 1020, 132, 10.1196/annals.1310.014 Quaranta, 2005, Mathematical modeling of cancer: The future of prognosis and treatment, Clin Chim Acta, 357, 173, 10.1016/j.cccn.2005.03.023 el-Kareh, 1997, Theoretical models for drug delivery to solid tumors, Crit Rev Biomed Eng, 25, 503, 10.1615/CritRevBiomedEng.v25.i6.20 Gadkar, 2005, Iterative approach to model identification of biological networks, BMC Bioinformatics, 6, 155, 10.1186/1471-2105-6-155 Fischer, 2005, Towards quantitative biology: Integration of biological information to elucidate disease pathways and to guide drug discovery, Biotechnol Annu Rev, 11, 1, 10.1016/S1387-2656(05)11001-1 Abbott, 2006, Simulating the hallmarks of cancer, Artif Life, 12, 617, 10.1162/artl.2006.12.4.617 Novak, 1999, Intelligent systems in medical diagnosis, Stud Health Technol Inform, 68, 700 Ulrich, 2006, Mathematical modeling: Epidemiology meets systems biology, Cancer Epidemiol Biomarkers Prev, 15, 827, 10.1158/1055-9965.EPI-06-0252 Cho, 2006, The application of systems biology to drug discovery, Curr Opin Chem Biol, 10, 294, 10.1016/j.cbpa.2006.06.025 Csukas, 2003, 283 Atri, 2006, New technologies and directed agents for applications of cancer imaging, J Clin Oncol, 24, 3299, 10.1200/JCO.2006.06.6159 Agrawal, 2005, New institute to study systems biology, Nat Biotechnol, 17, 743, 10.1038/11667 Khalil, 2005, Systems biology for cancer, Curr Opin Oncol, 17, 44, 10.1097/01.cco.0000150951.38222.16 Mahmud, 2005, The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells, Colloids Surf B Biointerfaces, 45, 82, 10.1016/j.colsurfb.2005.07.008 Hong, 2006, Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability, Bioconjug Chem, 17, 728, 10.1021/bc060077y Manunta, 2006, Gene delivery by dendrimers operates via different pathways in different cells, but is enhanced by the presence of caveolin, J Immunol Methods, 314, 134, 10.1016/j.jim.2006.06.007 Shukla, 2006, HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb, Bioconjug Chem, 17, 1109, 10.1021/bc050348p Manunta, 2004, Gene delivery by dendrimers operates via a cholesterol dependent pathway, Nucleic Acids Res, 32, 2730, 10.1093/nar/gkh595 Nan, 2005, Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck, J Drug Target, 13, 189, 10.1080/10611860500065187 Pujals, 2006, Mechanistic aspects of CPP-mediated intracellular drug delivery: Relevance of CPP self-assembly, Biochim Biophys Acta, 1758, 264, 10.1016/j.bbamem.2006.01.006 Remy-Kristensen, 2001, Role of endocytosis in the transfection of L929 fibroblasts by polyethylenimine/DNA complexes, Biochim Biophys Acta, 1514, 21, 10.1016/S0005-2736(01)00359-5 Miglietta, 2000, Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel, Int J Pharm, 210, 61, 10.1016/S0378-5173(00)00562-7 Bremer, 2006, Targeted induction of apoptosis for cancer therapy: Current progress and prospects, Trends Mol Med, 12, 382, 10.1016/j.molmed.2006.06.002 Huth, 2006, Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging, J Control Release, 110, 490, 10.1016/j.jconrel.2005.10.018 Phelps, 2003, Cytoskeletal motors and cargo in membrane trafficking: Opportunities for high specificity in drug intervention, Drug Discov Today, 8, 494, 10.1016/S1359-6446(03)02707-7 Takamori, 2006, Molecular anatomy of a trafficking organelle, Cell, 127, 831, 10.1016/j.cell.2006.10.030 Bhattacharya, 2005, Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling, FASEB J, 19, 1692, 10.1096/fj.05-3889fje Caviston, 2006, Microtubule motors at the intersection of trafficking and transport, Trends Cell Biol, 16, 530, 10.1016/j.tcb.2006.08.002 Haucke, 2006, Cargo takes control of endocytosis, Cell, 127, 35, 10.1016/j.cell.2006.09.012 Merisko-Liversidge, 2003, Nanosizing: A formulation approach for poorly-water-soluble compounds, Eur J Pharm Sci, 18, 113, 10.1016/S0928-0987(02)00251-8 Rabinow, 2004, Nanosuspensions in drug delivery, Nat Rev Drug Discov, 3, 785, 10.1038/nrd1494 Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine, Proc Natl Acad Sci USA, 92, 7297, 10.1073/pnas.92.16.7297 Krauze, 2005, Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging, Brain Res Brain Res Protoc, 16, 20, 10.1016/j.brainresprot.2005.08.003 Mortensen, 2006, Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy, Bioconjug Chem, 17, 284, 10.1021/bc050206v Langer, 2004, Designing materials for biology and medicine, Nature, 428, 487, 10.1038/nature02388 Alexander, 2001, Synthetic polymer systems in drug delivery, Expert Opin Emerg Drugs, 6, 345, 10.1517/14728214.6.2.345 Venkatesh, 2005, Applications of biomimetic systems in drug delivery, Expert Opin Drug Deliv, 2, 1085, 10.1517/17425247.2.6.1085 Oberdorster, 2005, Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles, Environ Health Perspect, 113, 823, 10.1289/ehp.7339 Sahoo, 2003, Nanotech approaches to drug delivery and imaging, Drug Discov Today, 8, 1112, 10.1016/S1359-6446(03)02903-9 Allen, 2004, Drug delivery systems: Entering the mainstream, Science, 303, 1818, 10.1126/science.1095833 Nijhara, 2006, Bringing nanomedicines to market: Regulatory challenges, opportunities, and uncertainties, Nanomed Nanotechnol Biol Med, 2, 127, 10.1016/j.nano.2006.04.005 Chavanpatil, 2006, Nanoparticles for cellular drug delivery: Mechanisms and factors influencing delivery, J Nanosci Nanotechnol, 6, 2651, 10.1166/jnn.2006.443 Szekerke, 1972, The use of macromolecules as carriers of cytotoxic groups (part I) conjugates of nitrogen mustards with proteins, polypeptidyl proteins and polypeptides, Neoplasma, 19, 199 Petrak, 2006, Nanotechnology and site-taregted drug delivery, J Biomater Sci Polymer Edn, 17, 1209, 10.1163/156856206778667497